Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325–36.

Article  CAS  PubMed  Google Scholar 

Yu G, Yin C, Wu F, Jiang L, Zheng Z, Xu D, et al. Gene mutation profile and risk stratification in AML1‑ETO‑positive acute myeloid leukemia based on next‑generation sequencing. Oncol Rep. 2019;42:2333–44.

CAS  PubMed  PubMed Central  Google Scholar 

Yin JA, O’Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012;120:2826–35.

Article  CAS  PubMed  Google Scholar 

Krauth MT, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, et al. High number of additional genetic lesions in acute myeloid leukemia with t (8; 21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. Leukemia. 2014;28:1449–58.

Article  CAS  PubMed  Google Scholar 

Zhang L, Cao Z, Ruan M, Zeng Q, Zhao L, Li Q, et al. Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia. Pediatr Blood Cancer. 2014;61:1761–6.

Article  CAS  PubMed  Google Scholar 

Freeman SD, Hourigan CS. MRD evaluation of AML in clinical practice: are we there yet? Hematol Am Soc Hematol Educ Program. 2019;2019:557–69.

Article  Google Scholar 

Pigazzi M, Manara E, Buldini B, Beqiri V, Bisio V, Tregnago C, et al. Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement. Haematologica. 2015;100:e99–101.

Article  PubMed  PubMed Central  Google Scholar 

Zhu HH, Zhang XH, Qin YZ, Liu DH, Jiang H, Chen H, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013;121:4056–62.

Article  CAS  PubMed  Google Scholar 

Hu GH, Cheng YF, Lu AD, Wang Y, Zuo YX, Yan CH, et al. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment. BMC Cancer. 2020;20:553.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ngai LL, Kelder A, Janssen JJWM, Ossenkoppele GJ, Cloos J. MRD tailored therapy in AML: what we have learned so far. Front Oncol. 2021;10:603636.

Article  PubMed  PubMed Central  Google Scholar 

Yu S, Lin T, Nie D, Zhang Y, Sun Z, Zhang Q, et al. Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes. Blood Cancer J. 2021;11:195.

Article  PubMed  PubMed Central  Google Scholar 

Qin YZ, Jiang Q, Wang Y, Jiang H, Xu LP, Zhao XS, et al. The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia. Blood Cancer J. 2021;11:67.

Article  PubMed  PubMed Central  Google Scholar 

Meddi E, Savi A, Moretti F, Mallegni F, Palmieri R, Paterno G, et al. Measurable residual disease (MRD) as a surrogate efficacy-response biomarker in AML. Int J Mol Sci. 2023;24:3062.

Article  PubMed  PubMed Central  Google Scholar 

Wang YY, Zhou GB, Yin T, Chen B, Shi JY, Liang WX, et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA. 2005;102:1104–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang YY, Zhao LJ, Wu CF, Liu P, Shi L, Liang Y, et al. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA. 2011;108:2450–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leukemia, Lymphoma Group, Chinese Society of Hematology Chinese Medical Association. Chinese guidelines for the diagnosis and treatment of relapsed/refractory acute myelogenous leukemia. Zhonghua Xue Ye Xue Za Zhi. 2021;42:624–7. (in Chinese)

Google Scholar 

Christen F, Hoyer K, Yoshida K, Hou HA, Waldhueter N, et al. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. Blood. 2019;133:1140–51.

Article  CAS  PubMed  Google Scholar 

Opatz S, Bamopoulos SA, Metzeler KH, Herold T, Ksienzyk B, et al. The clinical mutatome of core binding factor leukemia. Leukemia. 2020;34:1553–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haferlach T, Meggendorfer M. More than a fusion gene: the RUNX1-RUNX1T1 AML. Blood. 2019;133:1006–7.

Article  CAS  PubMed  Google Scholar 

Micol J, Pastore A, Inoue D, Duployez N, Kim E, Lee SC, et al. ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nat Commun. 2017;8:15429.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin H, Zhang Y, Yu S, Du X, Xu N, Shao R, et al. Venetoclax combined with azacitidine and homoharringtonine in relapsed/refractory AML: a Multicenter, Phase 2 Trial. J Hematol Oncol. 2023;16:42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Acute Myeloid Leukemia Version 2 https://www.nccn.org (2023).